Senti Biosciences (NASDAQ:SNTI - Get Free Report)'s stock had its "buy" rating restated by investment analysts at Chardan Capital in a report released on Thursday,Benzinga reports. They currently have a $12.00 price objective on the stock. Chardan Capital's price objective suggests a potential upside of 361.54% from the stock's current price.
Separately, Laidlaw started coverage on shares of Senti Biosciences in a research report on Friday, June 6th. They set a "buy" rating and a $5.00 target price on the stock.
Read Our Latest Analysis on Senti Biosciences
Senti Biosciences Price Performance
Senti Biosciences stock traded down $0.26 during midday trading on Thursday, hitting $2.60. The company's stock had a trading volume of 94,636 shares, compared to its average volume of 809,089. Senti Biosciences has a 1-year low of $1.52 and a 1-year high of $16.94. The company has a 50-day moving average price of $3.37 and a two-hundred day moving average price of $3.86. The company has a market cap of $67.81 million, a price-to-earnings ratio of -0.17 and a beta of 2.23.
Senti Biosciences (NASDAQ:SNTI - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported ($1.41) EPS for the quarter, missing the consensus estimate of ($0.56) by ($0.85). The firm had revenue of $1.30 million for the quarter, compared to the consensus estimate of $1.30 million. Sell-side analysts forecast that Senti Biosciences will post -14.54 EPS for the current year.
Institutional Trading of Senti Biosciences
Several large investors have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in shares of Senti Biosciences during the 4th quarter valued at $47,000. Renaissance Technologies LLC bought a new stake in shares of Senti Biosciences during the 4th quarter valued at $181,000. Heights Capital Management Inc. bought a new stake in shares of Senti Biosciences during the 1st quarter valued at $2,520,000. Finally, Nantahala Capital Management LLC bought a new stake in shares of Senti Biosciences during the 1st quarter valued at $2,984,000. Institutional investors own 25.73% of the company's stock.
Senti Biosciences Company Profile
(
Get Free Report)
Senti Biosciences, Inc operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications.
Featured Stories
Before you consider Senti Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Senti Biosciences wasn't on the list.
While Senti Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.